[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2019014845A - Compuestos de aminotiazol como inhibidores de la proteina quinasa. - Google Patents

Compuestos de aminotiazol como inhibidores de la proteina quinasa.

Info

Publication number
MX2019014845A
MX2019014845A MX2019014845A MX2019014845A MX2019014845A MX 2019014845 A MX2019014845 A MX 2019014845A MX 2019014845 A MX2019014845 A MX 2019014845A MX 2019014845 A MX2019014845 A MX 2019014845A MX 2019014845 A MX2019014845 A MX 2019014845A
Authority
MX
Mexico
Prior art keywords
protein kinase
kinase inhibitors
aminothiazole compounds
compounds
aminothiazole
Prior art date
Application number
MX2019014845A
Other languages
English (en)
Inventor
Chuan Shih
Weir-Torn Jiaang
Hiu-jen TSAI
Original Assignee
Chuan Shih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chuan Shih filed Critical Chuan Shih
Publication of MX2019014845A publication Critical patent/MX2019014845A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos de aminotiazol de la Fórmula (I) que se muestran a continuación y las composiciones farmacéuticas que contienen uno de tales compuestos: (ver Fórmula) También se describen métodos para inhibir una tirosina quinasa y tratar el cáncer asociado con una tirosina quinasa con uno de los compuestos de aminotiazol.
MX2019014845A 2017-06-13 2018-06-13 Compuestos de aminotiazol como inhibidores de la proteina quinasa. MX2019014845A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762518855P 2017-06-13 2017-06-13
PCT/US2018/037221 WO2018231910A1 (en) 2017-06-13 2018-06-13 Aminothiazole compounds as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2019014845A true MX2019014845A (es) 2020-08-06

Family

ID=64562741

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014845A MX2019014845A (es) 2017-06-13 2018-06-13 Compuestos de aminotiazol como inhibidores de la proteina quinasa.

Country Status (14)

Country Link
US (1) US10300061B2 (es)
EP (1) EP3638237B1 (es)
JP (1) JP6979595B2 (es)
KR (1) KR102372288B1 (es)
CN (1) CN110831596A (es)
AU (1) AU2018284249B2 (es)
BR (1) BR112019026577A8 (es)
CA (1) CA3064081C (es)
ES (1) ES2949616T3 (es)
MX (1) MX2019014845A (es)
MY (1) MY201291A (es)
TW (1) TWI667236B (es)
WO (1) WO2018231910A1 (es)
ZA (1) ZA202000107B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7301958B2 (ja) 2018-05-25 2023-07-03 オンコキューブ セラピューティクス エルエルシー 新規な抗がん薬候補としての非常に強力なｔａｃｃ３阻害剤
WO2021178485A1 (en) * 2020-03-06 2021-09-10 National Health Research Institutes Pyrimidine compounds and their pharmaceutical uses
US11299489B1 (en) 2020-11-19 2022-04-12 National Health Research Institutes Thiazole compounds as protein kinase inhibitors
KR20240005751A (ko) * 2021-04-12 2024-01-12 에이2에이 파마수티칼스, 잉크. 암 치료를 위한 조성물 및 방법
WO2023183520A1 (en) 2022-03-24 2023-09-28 A2A Pharmaceuticals, Inc. Compositions and methods for treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003285007A1 (en) * 2002-10-30 2004-06-07 Merck & Co., Inc. Kinase inhibitors
US20080242704A1 (en) * 2005-04-04 2008-10-02 Ab Science Substituted Oxazole Derivatives and their Use as Tyrosine Kinase Inhibitors
CA2610884A1 (en) 2005-06-09 2006-12-21 Merck & Co., Inc. Inhibitors of checkpoint kinases
GB0610909D0 (en) 2006-06-05 2006-07-12 Merck Sharp & Dohme Therapeutic treatment
KR101433629B1 (ko) 2006-09-11 2014-08-27 쿠리스 인코퍼레이션 아연 결합 부분을 함유한 티로신 키나아제 억제제
TW200906825A (en) 2007-05-30 2009-02-16 Scripps Research Inst Inhibitors of protein kinases
US9255072B2 (en) 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
MX2014001079A (es) * 2011-07-27 2014-09-12 Ab Science Derivados de oxazoly tiazol como inhibidores de la proteina quinasa selectiva (c-kit).
CN106279143A (zh) * 2015-05-11 2017-01-04 天津国际生物医药联合研究院 噻唑杂环类化合物及其制备方法和应用
WO2018106643A1 (en) * 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases

Also Published As

Publication number Publication date
BR112019026577A2 (pt) 2020-06-23
NZ759327A (en) 2021-08-27
CN110831596A (zh) 2020-02-21
MY201291A (en) 2024-02-15
WO2018231910A1 (en) 2018-12-20
AU2018284249B2 (en) 2021-06-24
ZA202000107B (en) 2020-12-23
JP2020523348A (ja) 2020-08-06
KR20200014350A (ko) 2020-02-10
EP3638237A1 (en) 2020-04-22
CA3064081C (en) 2023-03-21
US20180353509A1 (en) 2018-12-13
ES2949616T3 (es) 2023-10-02
EP3638237B1 (en) 2023-04-19
KR102372288B1 (ko) 2022-03-08
RU2019137573A (ru) 2021-05-24
JP6979595B2 (ja) 2021-12-15
BR112019026577A8 (pt) 2023-04-11
US10300061B2 (en) 2019-05-28
TWI667236B (zh) 2019-08-01
RU2019137573A3 (es) 2021-07-23
CA3064081A1 (en) 2018-12-20
TW201906836A (zh) 2019-02-16
AU2018284249A1 (en) 2019-12-12
EP3638237A4 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
MX2023005804A (es) Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
CR20220066A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
ZA201708667B (en) Tyrosine kinase inhibitors
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
MY194262A (en) Inhibitors of ret
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
ZA202000148B (en) Heterocyclic inhibitors of atr kinase
MX2019014845A (es) Compuestos de aminotiazol como inhibidores de la proteina quinasa.
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
EA201691916A1 (ru) Биарильные ингибиторы киназы
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
EA201691397A1 (ru) Хинолиновые ингибиторы киназы
EA033238B1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
EA201691549A1 (ru) Ариллактамные ингибиторы киназы
EP3500257A4 (en) KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
MX2018008507A (es) Inhibición de proteína relacionada con ataxia telangiectasia y rad3 (atr).